The following interests have been declared by the group: SS has received funding from Boehringer Ingelheim, Novartis, Bayer, Allergan, Roche, Opthea, Optos, Oculis, Oxurion and Apellis for consultancy, research and speaking at symposia. PB has attended Roche Diabetic Eye Disease and neovascular AMD advisory board meetings. LD has been the Principal Investigator for sponsored clinical trials with Bayer, Novartis, Allergan, Roche and Alimera. She has also received fees for speaking at meetings from Bayer and Novartis and sponsorship for attending a meeting from Novartis, Bayer, and Allergan. ZR: the Local Optical Committee Support Unit provides advice on services to primary care providers and commissioners. CY: the Macular Society has received grants from the following companies: Alcon, Allergan (AbbVie), Apellis, Bayer, Novartis, OKKO health, Oxsight, Roche, Vision Express. It has also received consultancy fees from Novartis and an honorarium for her attendance at meetings of the Roche global Retina Patient Forum. SM has been the Principal Investigator for sponsored clinical trials with Bayer, Novartis and Roche. He has also received fees for advisory boards, lecturing and travel grants for meetings from Bayer and Novartis. RC-N has received an honorarium from Bayer for attending a Bayer Ophthalmology Masterclass event. None from other authors.